G. Thomsen

Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial

N. Volkow, J. Holst, M. Gillum, 2022, JCI insight.

Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial

N. Volkow, P. Fisher, H. Benveniste, 2018, BMJ Open.

University of Southern Denmark Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence Study protocol of a randomised, double-blinded, placebo-controlled clinical trial

N. Volkow, P. Fisher, H. Benveniste, 2018 .

Syddansk Universitet Does glucagon-like peptide-1 ( GLP-1 ) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence Study protocol of a randomised , double-blinded , placebo-controlled clinical trial

N. Volkow, P. Fisher, H. Benveniste, 2018 .

Can long-term antibiotic treatment prevent progression of peripheral arterial occlusive disease? A large, randomized, double-blinded, placebo-controlled trial.

J. Lindholt, S. Juul, E. W. Henneberg, 2008, Atherosclerosis.

Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent

J. Holst, A. Fink-Jensen, G. Knudsen, 2020, Neurochemistry International.